Synthesis and Biological Evaluation of Phaeosphaeride A Derivatives as Antitumor Agents. 2018

Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
Laboratory of Chemical Modeling, Research Institute of Hygiene, Occupational Pathology and Human Ecology, Federal Medical Biological Agency, p/o Kuz'molovsky, 188663 Saint Petersburg, Russia. vvaavv@mail.ru.

New derivatives of phaeosphaeride A (PPA) were synthesized and characterized. Anti-tumor activity studies were carried out on the HCT-116, PC3, MCF-7, A549, К562, NCI-Н929, Jurkat, THP-1, RPMI8228 tumor cell lines, and on the HEF cell line. All of the compounds synthesized were found to have better efficacy than PPA towards the tumor cell lines mentioned. Compound 6 was potent against six cancer cell lines, HCT-116, PC-3, K562, NCI-H929, Jurkat, and RPMI8226, showing a 47, 13.5, 16, 4, 1.5, and 7-fold increase in anticancer activity comparative to those of etoposide, respectively. Compound 1 possessed selectivity toward the NCI-H929 cell line (IC50 = 1.35 ± 0.69 μM), while product 7 was selective against three cancer cell lines, HCT-116, MCF-7, and NCI-H929, each having IC50 values of 1.65 μM, 1.80 μM and 2.00 μM, respectively.

UI MeSH Term Description Entries
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072283 A549 Cells An immortalized cell line derived from human ADENOCARCINOMA, ALVEOLAR basal epithelial cells isolated from the lungs of a male patient in 1972. The cell line is positive for KERATIN, can synthesize LECITHIN, and contains high levels of POLYUNSATURATED FATTY ACIDS in its PLASMA MEMBRANE. It is used as a model for PULMONARY ALVEOLI function and virus infections, as a TRANSFECTION host, and for PRECLINICAL DRUG EVALUATION. A549 Cell Line,A549 Cell,A549 Cell Lines,Cell Line, A549,Cell Lines, A549,Cell, A549,Cells, A549
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045325 HCT116 Cells Human COLORECTAL CARCINOMA cell line. HCT 116 Cells,HCT-116 Cells,Cell, HCT 116,Cell, HCT-116,Cell, HCT116,Cells, HCT 116,Cells, HCT-116,Cells, HCT116,HCT 116 Cell,HCT-116 Cell,HCT116 Cell
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
June 2013, European journal of medicinal chemistry,
Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
January 2015, European journal of medicinal chemistry,
Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
February 2014, Bioorganic & medicinal chemistry letters,
Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
March 2014, Chemical biology & drug design,
Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
March 2014, Bioorganic & medicinal chemistry letters,
Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
January 2012, Journal of Asian natural products research,
Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
July 2018, European journal of medicinal chemistry,
Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
July 2005, Bioorganic & medicinal chemistry letters,
Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
September 2011, European journal of medicinal chemistry,
Victoria Abzianidze, and Petr Beltyukov, and Sofya Zakharenkova, and Natalia Moiseeva, and Jennifer Mejia, and Alvin Holder, and Yuri Trishin, and Alexander Berestetskiy, and Victor Kuznetsov
March 2011, Molecules (Basel, Switzerland),
Copied contents to your clipboard!